2018 Annual Conference on Vaccinology Research (ACVR) Call for Abstracts

The National Foundation for Infectious Diseases (NFID) invites abstract submissions of original research in the areas of: behavioral science and vaccine hesitancy; epidemiology and burden of disease; new and emerging vaccines; novel methods in disease detection and diagnosis; vaccine policy, programs, and practice; vaccine production, testing, and delivery technologies; and vaccine safety and monitoring. Abstracts are peer-reviewed for quality of research, educational and scientific content, and overall impact. Accepted abstracts are scheduled as either poster or oral presentations based on quality and anticipated interest.

How to Submit:

All abstracts must be submitted electronically through the ACVR online submission site (http://bit.ly/2018ACVRabstracts). All users will be required to create an account. Users may begin the submission process and return to saved proposals at any time up until the submission deadline. Abstracts submitted by email, fax, or mail will not be accepted. Incomplete abstracts will not be reviewed.


October 30, 2017  Call for Abstracts submission site opens
January 17, 2018  Abstract submission deadline (11:59 PM PST). No extensions will be granted.
February 2018          Notifications issued for all submitted abstracts
February 2018  Maurice R. Hilleman Early-Stage Career Investigator Award finalist notifications issued
March 12, 2018  Presenter registration deadline
April 23-25, 2018  2018 Annual Conference on Vaccinology Research

                                 Hyatt Regency Bethesda

                                 Bethesda, MD

Categories for Abstract Submission:

The submitting author must select the most appropriate subject category from the list below. The ACVR Scientific Planning Committee reserves the right to change the category to more appropriately reflect the abstract content.

  • Behavioral Science and Vaccine Hesitancy
  • Epidemiology and Burden of Vaccine-Preventable Diseases
  • New and Emerging Vaccines
  • Novel Methods in Disease Detection and Diagnosis
  • Vaccine Policy, Programs, and Practice
  • Vaccine Production, Testing, and Delivery Technologies
    • Preclinical Studies and Clinical Trials
    • Adjuvants
  • Vaccine Safety and Monitoring

Abstract Format:

All abstracts must be submitted in English and must reflect original work. Abstracts based on prior presentations with updated information and additional data generated and/or analyzed are permitted. Multiple submissions of the same abstract will automatically be rejected.

Abstracts must contain the following components:

     Abstract Title: (75 word limit)

       Use a concise title that summarizes the content

       Capitalize the first letter of each word, except for prepositions, articles, and species names

       Italicize all specific names of microorganisms and scientific organism names

       DO NOT use any of the following formats for the abstract title


       all lower case


       All Italics

       “Quotes around your abstract title”

     Background: (150 word limit) a concise statement of the issue under investigation or a hypothesis

     Methods: (200 word limit) the experimental methods used (including the statistical analyses employed)

     Results & Conclusions: (250 word limit) a summary of specific findings and results (statistical analyses used to support the conclusions should be included; concluding statements such as “the results will be discussed” or “to be completed” are not acceptable)

     Author(s): (limit of 10 authors) Submittals must include the First Author, Presenting Author (individual who will be presenting the research at the conference if accepted), and any co-authors of the work. Note that the full contact information and CVs will be requested for all authors. The system allows users to send an email to each of the authors for them to complete this information directly.

     Disclosures: NFID requires all presenters and reviewers to disclose all relevant financial relationships with any commercial interest in any amount, occurring within the past 12 months, that could create a conflict of interest. Disclosure information is reviewed in advance to manage and resolve any real or perceived conflict of interest that may affect the balance and scientific integrity of an educational presentation.

     Learning Objective(s): Users are required to submit at least one learning objective. Sample learning objectives are available at: www.nfid.org/professional-education/presenter-resources.

     References: Users are required to submit at least one literature reference/citation to support  research/data (two are preferred). Use the conventional style for listing references as referred by the American Medical Association (AMA) Manual of Style: A Guide for Authors and Editors. Sample references are available at: http://jama.jamanetwork.com/public/instructionsForAuthors.aspx#References.

It is the author’s responsibility to ensure that all submitted abstracts are correct. Any errors in spelling, grammar, or scientific fact in the abstract text may be reproduced as typed by the author. Corrections to accepted abstracts may be submitted through the online Abstract Resource Center no later than February 19, 2018. No requests for changes will be accepted after this date.


All abstract submissions will be reviewed by members of the ACVR Scientific Planning Committee for scientific merit and relevance to the field of vaccinology. Abstract submissions are reviewed for the following: a clearly stated hypothesis or issue; experimental and statistical methods used; specific findings (statements such as “the data will be presented,” are unacceptable); and specific conclusions (statements such as “the results will be discussed,” are unacceptable). Authors of accepted abstracts will be invited to present their work in a 10 minute oral presentation or as a poster presentation.

Poster and Oral Presenter Information:

Detailed information for preparing oral and/or poster presentations will be provided upon abstract acceptance. Oral presentations will be allotted a maximum of 10 minutes followed by 5 minutes for questions from the audience. Poster presentations will be displayed on standard poster boards, measuring 4 feet high by 8 feet wide (1.22 meters high by 2.44 meters wide), so the poster should be no wider than 6 feet (1.83 meters wide).

Registration & Attendance:

All abstract presenters must register for the conference and pay the appropriate registration fee no later than March 12, 2018 or their abstract will be withdrawn from the program. Presenters who fail to appear at the conference at the specified time(s) will forfeit their registration fee and future abstract submissions may be automatically disqualified from consideration. The conference organizer does not provide any support for travel costs or registration fees.

Abstract Publication:

All abstracts will be published in the onsite program book. Select presentations may be included in future publications with author permission.


Maurice R. Hilleman Early-Stage Career Investigator Award (www.nfid.org/awards/hilleman-award)

The Maurice R. Hilleman Early-Stage Career Investigator Award recognizes individuals in the early stages of their careers in any field of vaccinology. Awardees will receive $10,000 to support their research, will be recognized during the NFID luncheon at the 2018 ACVR, and will present a 10 minute summary of their research. In addition, the awardee will receive a travel stipend and complimentary registration for the 2019 Annual Conference on Vaccinology Research.

To apply for award consideration, applicants must:
  1. At the time of submission, be currently enrolled, recently completed training (e.g., internship, residency, fellowship, postdoctoral training, or similar educational program), or be within four years of having earned an advanced degree (masters or doctoral); and
  2. Submit an abstract under the ‘poster only’ or ‘poster or oral abstract’ submission categories. Finalists will be awarded a poster presentation slot at the 2018 ACVR. Following judging onsite, the winner will be announced and will present a 10 minute summary of their research during the conference.
  3. Acknowledge that the award is funded in part by Merck & Co., Inc. Awardees must be in a position to accept funding. Merck is required to report any direct/indirect funding in accordance with the Sunshine Act. Awardees of the Maurice R. Hilleman Early-Stage Career Investigator Award will be included in all mandatory reporting. All publications under the award must explicitly state that the awardees’ work has been performed as a Maurice R. Hilleman Early-Stage Career Investigator Award recipient. Acknowledgement must also be given to NFID and Merck as the sponsors supporting the award.